A new study of more than 2,900 patients provides evidence that it's likely best to use as little corticosteroid medicine as ...
For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...
Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...
Recurrent pericarditis occurs in one fifth of patients with systemic lupus erythematosus, with higher rates being observed in ...
In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.
July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...
Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...
Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...
Objective At least half of patients with systemic lupus erythematosus (SLE) develop organ damage as a consequence of autoimmune disease or long-term therapeutic steroid use. This study synthesised ...
Lupus involves unpredictable symptom flares and potential changes in brain chemistry that may increase your risk of experiencing depression and anxiety. Lupus is a chronic (long-term) autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results